IDH1 and cancer: TERT promoter (TERTp) mutations are the most common non-coding mutations in cancer, including the majority of IDH1 wild-type (IDH1-WT) primary glioblastoma (GBM) (Huang et al., 2013; Horn et al., 2013; Remke et al., 2013; Quaas et al., 2014; Zehir et al., 2017; Killela et al., 2013; Aquilanti et al., 2021; Vinagre et al., 2013; Arita et al., 2013; Patel et al., 2020).